An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults

Trial Profile

An Open-Label, Sequential, 3-Period Study to Evaluate Pharmacokinetics of Coadministered Raltegravir (Isentress) and Lopinavir-Ritonavir (Kaletra) in Healthy Adults

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jun 2008

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Raltegravir (Primary)
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Acronyms RAL-KAL
  • Most Recent Events

    • 16 Jun 2008 Additional trial identifier 78958 reported by ClinicalTrials.gov.
    • 16 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top